Trial · NCT02334306
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 | Placebo | -2.3 | Standard Error 0.8 | Scores on a scale | |
| Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 | MEDI5872 210 mg | -3.8 | Standard Error 0.9 | Scores on a scale | |
| Ratio to Baseline in Peripheral Blood Biomarkers at Day 99 | Placebo | Plasma Cell Levels | 0.70 | Standard Error 0.24 | Ratio |
| Ratio to Baseline in Peripheral Blood Biomarkers at Day 99 | MEDI5872 210 mg | Plasma Cell Levels | 0.65 | Standard Error 0.24 | Ratio |
| Ratio to Baseline in Peripheral Blood Biomarkers at Day 99 | Placebo | TFH Cells | 0.94 | Standard Error 0.27 | Ratio |
| Ratio to Baseline in Peripheral Blood Biomarkers at Day 99 | MEDI5872 210 mg | TFH Cells | 0.62 | Standard Error 0.27 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | Placebo | Total Plasma Cells | 1.32 | Standard Error 0.13 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | MEDI5872 210 mg | Total Plasma Cells | 1.15 | Standard Error 0.11 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | Placebo | CD4/ICOS TFH Cells | 1.76 | Standard Error 0.21 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | MEDI5872 210 mg | CD4/ICOS TFH Cells | 0.75 | Standard Error 0.18 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | Placebo | PD-1/ICOS TFH Cells | 1.06 | Standard Error 0.19 | Ratio |
| Ratio to Baseline in Minor Salivary Gland Tissue Biomarkers at Day 99 | MEDI5872 210 mg | PD-1/ICOS TFH Cells | 1.07 | Standard Error 0.16 | Ratio |
| Ratio to Baseline in Focus Score at Day 99 | Placebo | 0.79 | Standard Deviation 0.53 | Ratio | |
| Ratio to Baseline in Focus Score at Day 99 | MEDI5872 210 mg | 0.96 | Standard Deviation 0.50 | Ratio | |
| Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Patient Reported Index (ESSPRI) Score at Day 99 | Placebo | -1.0 | Standard Error 0.5 | Scores on a scale | |
| Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Patient Reported Index (ESSPRI) Score at Day 99 | MEDI5872 210 mg | -0.6 | Standard Error 0.5 | Scores on a scale | |
| Percentage of ESSDAI Responders at Day 99 | Placebo | ESSDAI [3] | 18.8 | Percentage of participants | |
| Percentage of ESSDAI Responders at Day 99 | MEDI5872 210 mg | ESSDAI [3] | 43.8 | Percentage of participants | |
| Percentage of ESSDAI Responders at Day 99 | Placebo | ESSDAI [4] | 18.8 | Percentage of participants | |
| Percentage of ESSDAI Responders at Day 99 | MEDI5872 210 mg | ESSDAI [4] | 43.8 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02334306/results